Jim Wassil Sells 2,250 Shares of Vaxcyte (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 2,250 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $49.52, for a total value of $111,420.00. Following the sale, the chief operating officer owned 158,494 shares in the company, valued at approximately $7,848,622.88. The trade was a 1.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jim Wassil also recently made the following trade(s):

• On Friday, May 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $56.83, for a total value of $127,867.50.
• On Tuesday, March 10th, Jim Wassil sold 7,395 shares of Vaxcyte stock. The stock was sold at an average price of $58.88, for a total value of $435,417.60.

Vaxcyte Stock Performance

PCVX opened at $48.76 on Friday. The business’s fifty day moving average is $55.38 and its two-hundred day moving average is $52.76. The company has a market cap of $7.04 billion, a price-to-earnings ratio of -7.09 and a beta of 1.24. Vaxcyte, Inc. has a one year low of $29.08 and a one year high of $65.00.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Wednesday, May 6th. The company reported ($2.30) EPS for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same period in the prior year, the firm posted ($1.04) earnings per share. On average, analysts predict that Vaxcyte, Inc. will post -7.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on PCVX shares. Wall Street Zen downgraded Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a report on Wednesday, April 8th. Jefferies Financial Group reissued a “buy” rating on shares of Vaxcyte in a report on Tuesday, March 10th. Finally, BTIG Research boosted their price target on Vaxcyte from $85.00 to $89.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $86.00.

Hedge Funds Weigh In On Vaxcyte

Institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. raised its holdings in shares of Vaxcyte by 30.6% in the third quarter. JPMorgan Chase & Co. now owns 1,565,036 shares of the company’s stock worth $56,373,000 after acquiring an additional 366,266 shares during the last quarter. Pivotal bioVenture Partners Investment Advisor LLC increased its stake in Vaxcyte by 5.2% in the third quarter. Pivotal bioVenture Partners Investment Advisor LLC now owns 1,372,425 shares of the company’s stock valued at $49,435,000 after purchasing an additional 67,300 shares during the last quarter. Westfield Capital Management Co. LP increased its stake in Vaxcyte by 21.6% in the third quarter. Westfield Capital Management Co. LP now owns 3,732,715 shares of the company’s stock valued at $134,452,000 after purchasing an additional 663,817 shares during the last quarter. HighVista Strategies LLC increased its stake in Vaxcyte by 159.4% in the third quarter. HighVista Strategies LLC now owns 86,802 shares of the company’s stock valued at $3,127,000 after purchasing an additional 53,345 shares during the last quarter. Finally, Bridgefront Capital LLC increased its stake in Vaxcyte by 127.2% in the third quarter. Bridgefront Capital LLC now owns 24,325 shares of the company’s stock valued at $876,000 after purchasing an additional 13,617 shares during the last quarter. 96.78% of the stock is owned by institutional investors and hedge funds.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.